Invus

Invus recognizes that every company is unique and that extraordinary business performance cannot be achieved by following a formulaic approach. Due to their unique structure, they have a great deal of flexibility in the types of companies and situations where they can get involved. Perhaps most importantly, they know that real transformation takes time and that it’s never a straight line. They fully align their incentives with their partners and have the wherewithal and long-term commitment to see through any bumps along the way. They have been successfully empowering owner-managers since 1985. They have been reinvesting the same pool of money from the same group of European families (through their Artal investment vehicle) since their founding. Today they manage over $4 billion in an evergreen fund and work out of offices in New York, London, Paris and Hong Kong.

Philippe J. Amouyal

MD, Private Equity

JB

Justin Barstein

MD, Private Equity

Evren Bilimer

MD, Private Equity

FC

Francis Cukierman

MD, Private Equity

Raymond Debbane

President and CEO

JM

Jonas M. Fajgenbaum

MD, Private Equity

Benjamin Felt

MD, Private Equity

AG

Aflalo Guimarães

MD, Private Equity

Chris Jiang

Director, Private Equity

MM

Matthew Maslow

Director of Public Equity for New York

CS

Christopher Sobecki

MD, Private Equity

Luc Ta-Ngoc

MD, Private Equity

171 past transactions

Vigil Neuroscience

Series B in 2021
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Arcus Biosciences, Inc.

Series B in 2016
Arcus Biosciences is biotech company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub.

Ambrx, Inc.

Private Equity Round in 2020
Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

Zenflow, Inc.

Series A in 2018
Zenflow, Inc. develops and markets a spring device that provides relief for permanent BPH symptoms in men. The company provides solutions for urinary obstruction without destroying tissues. It offers its products for patients and urologists. The company was formerly known as Torix Medical, Inc. The company was founded in 2014 and is based in San Francisco, California.

Dropee.com

Pre Seed Round in 2017
Dropee is a SaaS-enabled marketplace that connects local independent retailers with brands in South East Asia via an ordering app. The marketplace's unique value proposition makes it easier for businesses both big and small to manage their procurement and supply chain ecosystem. It allows businesses to get connected in order to buy and sell in bulk and the enterprise solution allows businesses to streamline their operational processes to work more efficiently and effectively. Dropeee’s platform connects suppliers with small-to-medium enterprise (SME) business owners in real-time to streamline the product fulfillment process and facilitate bulk purchases through a suite of enterprise solutions. The supply-chain in Malaysia and across Southeast Asia lacks meaningful real-time connectivity between suppliers and retailers. The modern, digital approach to the wholesale industry allows retailers to discover, purchase, and manage inventories for their store all on a single marketplace platform.

Curious AI Oy

Venture Round in 2017
Deep good. Unsupervised better. The Curious AI Company is making the digital co-workers of the future. The Curious AI Company develops artificial general intelligence (AI). The company focuses on autonomous and interactive machine learning technologies. Building on more than two decades of work in bio-inspired AI by founder Harri Valpola, PhD, Curious AI delivers industrial pilot projects while building a long-term, complete AI deep tech portfolio.

Health Data Analytics Institute

Venture Round in 2020
Health Data Analytics Institute is created a predictive platform that transcends the understanding of healthcare data and connects it to quantifiable, actionable information that benefits patients, providers, and society. But we don’t just translate data, we transform it into a continuum of insights — applicable across all touch points in an individual’s dynamic health journey. It’s deep knowledge that quantifies longevity, health status, health risks, and health costs. But that’s just the start.

BioNTech AG

Series B in 2019
BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

Future Finance

Series B in 2016
Future Finance is a non-government lender that offers student loans. Its mission is to provide loans for students that are simple, straightforward, and based on where they're heading, not where they've been. Future Finance helps students focus on what matters. Therefore, it aims to ensure everyone has the freedom to focus on their studies or kickstart their career whatever their financial background may be. It was founded in 2014 by Brian Norton and Vishal Garg and is headquartered in Dublin.
Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

Kyn Therapeutics

Series B in 2021
Ikena Oncology is dedicated to bringing next generation oncology therapies to patients suffering from cancer. Ikena Oncology are committed to leveraging our unique understanding of the complex biologic pathways that drive the formation and spread of cancers to discover and develop novel, patient-directed therapies. Selecting patients for treatment in clinical studies with biomarkers we develop is at the core of our strategy.

Foghorn Therapeutics Inc.

Venture Round in 2019
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.

Zero Motorcycles Inc.

Series A in 2010
Zero Motorcycles, Inc. manufactures and supplies electric motorcycles. It offers street, dirt, and dual sport motorcycles; and accessories, apparel, fairings and bodywork, parts, tires and wheels, and upgrades. The company sells its products through dealers and online. The company has a strategic partnership with Polaris Inc. Zero Motorcycles, Inc. was formerly known as Electricross, Inc. The company was founded in 2006 and is based in Scotts Valley, California with an additional office in Noord-Scharwoude, the Netherlands.

Flare Therapeutics

Series B in 2023
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.

Asher Bio

Series B in 2021
Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer. The company was founded in 2019 and headquartered in San Francisco, California.

Yumanity Therapeutics, Inc.

Venture Round in 2020
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award-winning protein folding expert, Susan Lindquist, and renowned biotech industry leader, Tony Coles, Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS.

Achilles Therapeutics

Series C in 2020
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

MOMA Therapeutics

Series B in 2022
MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.

Asher Bio

Series A in 2021
Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer. The company was founded in 2019 and headquartered in San Francisco, California.

Elixir Medical

Series A in 2005
Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, CA, specializes in developing products that combine state-of-the-art medical devices with advanced pharmaceuticals. The company's next-generation drug-eluting stent systems are designed to optimize localized drug delivery to provide a safe and effective treatment for cardiovascular patients.

Jumbotail

Series C in 2021
Jumbotail Technologies Pvt. Ltd. owns and operates an online marketplace for wholesalers to sell their products and services. The company was founded in 2015 and is based in Bengaluru, India.

Flare Therapeutics

Series A in 2021
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.

Snag

Series D in 2016
Snagajob is the platform for hourly work with 100 million registered hourly workers and 470,000 employer locations nationwide. With Snagajob, hourly workers find work more easily and employers staff up faster, hire smarter and keep shifts filled. Snagajob's platform for jobs and shifts allows people to land the right work while ensuring employers find the right workers when and where they need them. Snagajob was founded in 1999 and is based in Glen Allen, Virginia, United States.

Ring Therapeutics

Series B in 2021
Ring Therapeutics is a multi-product platform company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy. Founded by Flagship Pioneering, Ring is pioneering the first redosable and targetable gene therapy platform by harnessing the biology of the human commensal virome. The company is expanding the applications of gene therapy beyond gene replacement, enabling a much wider array of modalities and mechanisms to treat previously inaccessible diseases.
PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

FlatFrog Laboratories AB

Venture Round in 2010
FlatFrog's mission is to bring to life the exciting new world of multi-touch computing and applications. Designed from inception for volume production, our patented technologies enable unmatched in-glass multi-touch performance for large and flat displays. FlatFrog was founded by Ola Wassvik and serial entrepreneur Christer FÃ¥hraeus. The company is privately held with headquarters in Lund, Sweden, near the bridge to Copenhagen, Denmark.

Leyden Labs

Series B in 2022
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Abound Solar

Venture Round in 2008
Abound Solar produces next-generation, thin film photovoltaic modules intended to deliver the lowest levelized cost of electricity.

BioNTech AG

Series A in 2018
BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
Scorpion Therapeutics, Inc., a biotechnology company, develops next-generation precision oncology technologies for the treatment of cancer. The company develops precision oncology drugs in three areas, including therapies against known oncogenes; agents for known but currently undruggable cancer targets; and drugs for new targets. Scorpion Therapeutics, Inc. was founded in 2020 and is based in Boston, Massachusetts.

Korro Bio

Series B in 2022
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms. Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. In 2018,

Thrive Earlier Detection

Series B in 2020
Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3.

Marlette Funding, LLC

Venture Round in 2015
Marlette Funding is a financial tech company tasked to empower customers. It specializes in online lending services providing a frictionless application and a fast funding process. It has facilitated over $7B in loans to more than 350,000 people who use the loans to finance large purchases or consolidate and pay off debt. It was incorporated in 2013 and is based in Wilmington, Delaware.
Senti Biosciences is a team of bioengineers, scientists, and entrepreneurs on a mission to treat the most complex and challenging diseases. Led by pioneers in synthetic biology and computation, Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development. Senti Biosciences is a resident company of Johnson & Johnson Innovation, JLABS at South San Francisco (JLABS @ SSF).

Future Finance

Series C in 2018
Future Finance is a non-government lender that offers student loans. Its mission is to provide loans for students that are simple, straightforward, and based on where they're heading, not where they've been. Future Finance helps students focus on what matters. Therefore, it aims to ensure everyone has the freedom to focus on their studies or kickstart their career whatever their financial background may be. It was founded in 2014 by Brian Norton and Vishal Garg and is headquartered in Dublin.

PACT Pharma, Inc.

Series B in 2018
Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.The company's therapies help in the identification of neo-epitopes that serve as private mutations for each patient's cancer as well as creates an opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens, enabling physicians to recognize and remove each patient's cancer cells.

Onxeo SA

Post in 2022
Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma. Onxeo is headquartered in Paris, France.

Zero Motorcycles Inc.

Venture Round in 2012
Zero Motorcycles, Inc. manufactures and supplies electric motorcycles. It offers street, dirt, and dual sport motorcycles; and accessories, apparel, fairings and bodywork, parts, tires and wheels, and upgrades. The company sells its products through dealers and online. The company has a strategic partnership with Polaris Inc. Zero Motorcycles, Inc. was formerly known as Electricross, Inc. The company was founded in 2006 and is based in Scotts Valley, California with an additional office in Noord-Scharwoude, the Netherlands.

Les Nouveaux Fermiers

Funding Round in 2022
Les Nouveaux Fermiers cultivates a passion for taste, the real, the healthy, and the impact on the planet. It reinvents meat from natural and local plant ingredients to better feed the planet. Its products today represent 11 times less CO2 and 10 times less water than meat production. It was founded in 2019 and is headquartered in Paris, France.

E-Color

Venture Round in 2000
E-Color develops software solutions for color consistency and optimization on the Web. It delivers enhanced images while shopping online, printing digital photos, playing video games, and watching DVD movies. E-Color, Inc. was formerly known as Sonnetech, Ltd.

Evox Therapeutics Limited

Series C in 2021
Evox Therapeutics Limited develops a modular platform for clinical translation of exosome-based therapeutics. The company develops extracellular vesicles-based nucleic acid and protein delivery technology. Its technology aims to hitch a ride on tiny particles called exosomes, which the body uses to transport molecules between cells. Evox Therapeutics Limited was founded in 2016 and is based in Oxford, United Kingdom.

3-V Biosciences

Venture Round in 2021
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases such as liver disease NASH and specific cancers, with a focus on targeting dysfunctional metabolic pathways. It was founded in 2007 and headquartered in San Mateo, California.
Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Bright Peak Therapeutics

Series B in 2021
Bright Peak Therapeutics is a biotechnology company with a platform capable of chemically synthesizing and optimizing natural proteins such as cytokines.

Opera Solutions

Private Equity Round in 2011
Big data analytics

HOOKIPA Pharma Inc.

Series D in 2019
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Viseon Spine

Series B in 2020
Viseon, Inc. operates as a medical device company. It has developed the Voyant technology for use in both posterior and lateral access MIS spine procedures. The company’s technology offers a single-use disposable alternative to surgical microscopes, endoscopes and loupes, projecting the operative field onto a high definition flat panel display within the OR and to remote locations. Viseon, Inc. was incorporated in 2017 and is based in Irvine, California.
KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Curious AI Oy

Seed Round in 2015
Deep good. Unsupervised better. The Curious AI Company is making the digital co-workers of the future. The Curious AI Company develops artificial general intelligence (AI). The company focuses on autonomous and interactive machine learning technologies. Building on more than two decades of work in bio-inspired AI by founder Harri Valpola, PhD, Curious AI delivers industrial pilot projects while building a long-term, complete AI deep tech portfolio.

ImCheck Therapeutics SAS

Series C in 2022
ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

Gossamer Bio, Inc.

Post in 2022
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.

ViraCyte

Post in 2022
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials. The company was founded in 2013 and headquartered in Houston, Texas.

Zero Motorcycles Inc.

Venture Round in 2012
Zero Motorcycles, Inc. manufactures and supplies electric motorcycles. It offers street, dirt, and dual sport motorcycles; and accessories, apparel, fairings and bodywork, parts, tires and wheels, and upgrades. The company sells its products through dealers and online. The company has a strategic partnership with Polaris Inc. Zero Motorcycles, Inc. was formerly known as Electricross, Inc. The company was founded in 2006 and is based in Scotts Valley, California with an additional office in Noord-Scharwoude, the Netherlands.
Scholar Rock, Inc., a biotechnology company, discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

Omega

Series C in 2021
Omega Therapeutics, Inc. develops genomic medicines to cure diseases. The company focuses on precision tuning to activate the human genome’s native capacity to treat and cure diseases. It engages in designing, engineering, and manufacturing Epigenomic Controllers to target the GenomStats for the cell types of interest, with the ability to downregulate or upregulate genomic activity for therapeutic effect. Omega Therapeutics, Inc. was formerly known as VL42, Inc. and changed its name to Omega Therapeutics, Inc. in August 2017. The company was founded in 2016 and is based in Cambridge, Massachusetts.

EQRx

Post in 2021
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Cava Group, Inc.

Series F in 2021
Cava Group, Inc. owns and operates a chain of Greek and Mediterranean restaurants. It offers salads, dips, spreads, toppings, and dressings. The company has strategic partnerships with Garden School Foundation, Sow Much Good, Urban Roots, and Future Chefs. Cava Group, Inc. was founded in 2006 and is headquartered in Washington, District Of Columbia.

ElevateBio

Series C in 2021
ElevateBio is a operator of a portfolio of cell and gene therapy companies intended to develop, manufacture and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's most innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.
Repertoire Immune Medicines is a clinical stage biotechnology company working to unleash the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.

Wiloki

Venture Round in 2021
Wiloki is an innovative and motivating platform for children and teenagers aged 7 to 14. The personalized educational tool, enriched with artificial intelligence, intends to develop in Europe and enrich its educational content offer.

Moderna Therapeutics

Series E in 2015
Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

Fog Pharmaceuticals, Inc.

Venture Round in 2021
FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. FogPharma is laser-focused and unstoppable in its mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years.

Metacrine

Series C in 2018
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

MarkaVIP

Series A in 2011
Markavıp is an exclusive, invitation-only online shopping community focused on the Middle Eastern market. The website specializes in offering flash sales to its customers. Markavıp was founded by Ahmed Alkhatib, who previously spent 12 years in Silicon Valley working in the e-commerce industry. The website enjoys memberships from over 3 million exclusive members across eight Arabic speaking countries including Jordan, Saudi Arabia, UAE, Qatar, Kuwait, Lebanon, Bahrain, and Oman.

Lycia Therapeutics

Series B in 2021
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.

Jahia

Venture Round in 2015
Jahia is a leading open source User eXperience Platform (UXP) vendor, relentlessly working at transforming a silo industry into a user-driven one, beyond technology constraints. Each solution provided by Jahia stems from Jahia’s Digital Industrialization vision: to streamline Enterprise digital projects across all channels and truly accelerate corporate-wide deployments, by bridging the IT/Marketing lifecycle gap. Founded in 2002 and headquartered in Geneva, Switzerland, Jahia Solutions Group has its North American headquarters in Washington DC, with offices in Chicago, Toronto and throughout Europe. Jahia counts hundreds of global brands and governmental organizations among its loyal customers, in more than 20 countries across the globe. Early 2015, the company announced its first round of funding from Invus for €20 millions

Laronde

Series B in 2021
Laronde is pioneering a platform that offers a completely novel way of modulating human biology. Endless RNA™ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.

ViaCyte, Inc.

Series D in 2021
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

ezCater

Series D in 2021
ezCater, Inc. provides online catering ordering solutions for small start-ups and Fortune 500 companies. Its solutions enable users to order food online for meetings. The company offers ezManage, a catering management platform; and ezOrdering that provides restaurants with means to accept online catering orders on their own website. ezCater, Inc. was founded in 2007 and is based in Boston, Massachusetts. It has an additional office in Denver, Colorado.

Olive

Series A in 2020
At Olive we are on a mission to eliminate the hassles of online shopping while simultaneously creating a marketplace that is built for a more sustainable future. Reimagining online shopping from the ground up, we are building a technology platform to power the most convenient and sustainable e-commerce experience. When you shop at hundreds of our retail partners, you receive consolidated cardboard-free deliveries in secure 2-way Olive Shippers with crazy simple returns – just request a pickup with a single click in the Olive app, drop in any returns, and we handle the rest.
Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

PatientsLikeMe, Inc.

Series A in 2007
PatientsLikeMe is a personalized health network of an integrated community, health management, and real-world data platform. It helps people find new options for treatments, connect with others, and take action to improve their outcomes. The company has worked with every major pharmaceutical company and a range of government organizations to bring the patient voice to research, development, and public policy. With more than 600,000 members, PatientsLikeMe is a trusted source for real-world disease information and a clinically robust resource that has published more than 100 research studies. The Boston, Massachusetts-located company was founded by Ben Heywood, James Heywood, and Jeff Cole in 2004

Iteos Therapeutics S.A.

Series B in 2020
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Talaris Therapeutics

Series B in 2020
Talaris Therapeutics is a operator of a biotechnology company engaged in the development of innovative cellular therapies. The company's proprietary allogeneic cell therapy product has shown to induce tolerance in recipients of solid organ transplants from unmatched and unrelated donors, enabling living donor kidney transplant recipients to wean completely off immunosuppression one year after transplant.

Vascular Dynamics

Venture Round in 2022
Vascular Dynamics, Inc. develops and commercializes a catheter-delivered implant for the treatment of drug-resistant hypertension. It offers MobiusHD, an hypertension treatment amplifying the natural baroreceptor response in the carotid sinus with a minimally invasive procedure to stimulate vasodilation, reduce heart rate, modulate kidney response, and decrease blood pressure. The company was founded in 2008 and is based in Irvine, California.

LifeMine Therapeutics

Series C in 2022
LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Engine Biosciences

Series A in 2021
Engine Biosciences Pte. Ltd. develops a validated platform for drug discovering, developing combination therapeutics, and cellular reprogramming. The company's artificial intelligence and genetic perturbation platform allows researchers and drug developers to uncover the gene interactions and biological networks. It provides test therapies that specifically target genetic interactions, and make analyses and predictions for precision medicine applications. The platform provides drug discovery, such as target discovery, drug repositioning, repurposing, pathway, and massive online analysis (MoA) analysis. It caters to the American fortune 500 companies and research institutions. The company was founded in 2014 and is based in Singapore.

Lyndra Inc

Series C in 2021
Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximize global health impact and lower overall healthcare costs.

Abata Therapeutics

Series A in 2021
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with progressive multiple sclerosis (MS) and other severe autoimmune and inflammatory diseases.

Seer

Series C in 2019
Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurological diseases, drive earlier treatment and improve patient outcomes.
Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

Amount

Series D in 2021
Amount, Inc. designs and develops mobile banking solutions for financial institutions. The company offers Amount 360, a cloud-based solution that provides full-stack solutions, omnichannel integration, mitigation strategies, integration hubs, and a proprietary fraud model. The company also offers solutions for personal loans, credit cards, deposit accounts, and point-of-sale. Amount, Inc. was incorporated in 2018 and is based in Chicago, Illinois.

Neumora Therapeutics

Series A in 2021
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Generation Bio Co.

Series B in 2018
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.

Noema Pharma

Series A in 2020
Noema Pharma AG operates as a biotechnology company. The company develops therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. It develops and commercializes therapies for conditions affecting the nervous system, including Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. Noema Pharma AG was founded in 2019 and is based in Basel, Switzerland.

TigerConnect, Inc.

Series C in 2015
TigerConnect is a provider of clinical communication solutions, TigerConnect helps physicians, nurses, and other staff communicate and collaborate more effectively, accelerating productivity, reducing costs, and improving patient outcomes. Trusted by more than 4,000 healthcare organizations, TigerConnect maintains 99.99% uptime and processes over 10 million messages each day. Its category-leading product innovations and advanced integrations with critical hospital systems deliver high value for hospitals and large health systems. Their commitment to client success is reflected in their broad support organization that works directly with clients at every stage to streamline communication workflows and achieve the highest possible ROI. The company was incorporated in 2010 and is headquartered in Santa Monica, California.

Escale

Series C in 2019
Escale is a technology marketing and sales company. It is displacing the traditional outsourced agency & outsourced sales model, which has misaligned incentives, fails at leveraging data across online-to-offline conversion funnels and creates sub-par customer experiences. Via Escale's platform, it acquires customers for major B2C brands, managing the entire marketing and sales funnel from demand generation online through closing the final sales with our in-house performance sales center. It is paid 100% in a commission model for each customer it acquires and all marketing spend comes from its own investment to ensure they are truly aligned for performance and have full control over their own decisions. Escale was founded by Matthew Kligerman and Ken Diamond in 2013; and is headquartered in Sao Paulo, Brazil.

SDC Materials,Inc.

Series B in 2009
SDCmaterials, Inc is a privately held company that was founded in 2004 with a vision centered on Revolutionizing Materials Engineering. Their corporate mission is to create novel, high value, nano‐enhanced products that are easily integrated into Their customers’ manufacturing processes. The company’s primary focus is emission control catalyst ingredients for the automobile industry. SDC has developed proprietary catalytic materials fabrication and integration processes that are enabling step‐function improvements in the performance efficiencies of the underlying precious metals that are key to emissions control.

Renovis

Series E in 2003
Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.

Locana

Series B in 2020
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.

Imvax, Inc.

Series C in 2020
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers with unmet medical needs. Its product, IGV-001, is an autologous tumor cell vaccine that delivers a multi-pronged response against tumor cells by leveraging the patient’s immune system as a defense mechanism. The company was incorporated in 2015 by David W. Andrews, Craig Hooper, Arthur W. Howe, and Peter B. Corr in Philadelphia, Pennsylvania.

MarkaVIP

Series B in 2012
Markavıp is an exclusive, invitation-only online shopping community focused on the Middle Eastern market. The website specializes in offering flash sales to its customers. Markavıp was founded by Ahmed Alkhatib, who previously spent 12 years in Silicon Valley working in the e-commerce industry. The website enjoys memberships from over 3 million exclusive members across eight Arabic speaking countries including Jordan, Saudi Arabia, UAE, Qatar, Kuwait, Lebanon, Bahrain, and Oman.

Celtaxsys

Series E in 2018
Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded in 2007 and is based in Atlanta, Georgia.

Curious AI Oy

Convertible Note in 2016
Deep good. Unsupervised better. The Curious AI Company is making the digital co-workers of the future. The Curious AI Company develops artificial general intelligence (AI). The company focuses on autonomous and interactive machine learning technologies. Building on more than two decades of work in bio-inspired AI by founder Harri Valpola, PhD, Curious AI delivers industrial pilot projects while building a long-term, complete AI deep tech portfolio.

E-Color

Venture Round in 2000
E-Color develops software solutions for color consistency and optimization on the Web. It delivers enhanced images while shopping online, printing digital photos, playing video games, and watching DVD movies. E-Color, Inc. was formerly known as Sonnetech, Ltd.

Element Science

Series C in 2020
Element Science is a medical device and digital health company that develops solutions at the intersection of clinical-grade wearable devices, machine learning algorithms, and lifesaving therapies to address the needs of high-risk cardiovascular patients, primarily as they transition from the hospital to home. The company developing a proprietary next-generation wearable digital platform that unites patient-centric human factor engineering, sophisticated machine learning algorithm development principles, and rigorous electromechanical medical device development standards. The company was founded in 2011 and is headquartered in San Francisco, California.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

Escale

Series C in 2021
Escale is a technology marketing and sales company. It is displacing the traditional outsourced agency & outsourced sales model, which has misaligned incentives, fails at leveraging data across online-to-offline conversion funnels and creates sub-par customer experiences. Via Escale's platform, it acquires customers for major B2C brands, managing the entire marketing and sales funnel from demand generation online through closing the final sales with our in-house performance sales center. It is paid 100% in a commission model for each customer it acquires and all marketing spend comes from its own investment to ensure they are truly aligned for performance and have full control over their own decisions. Escale was founded by Matthew Kligerman and Ken Diamond in 2013; and is headquartered in Sao Paulo, Brazil.

Thrive Market

Series B in 2016
Thrive Market, Inc. operates a membership-based online shopping club that gives access to wholesome food and products in everyday sizes at wholesale prices. The company offers products in food, health, babies and kids, home, and pet, as well as beauty, bath, and body categories. It serves residential and commercial customers in the United States. The company was incorporated in 2015 and is based in Culver City, California.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

KNIME

Series A in 2017
KNIME offers open-source enterprise solutions and services. KNIME is the key contributor to KNIME Analytics Platform, an open-source platform for intuitive, integrative data science. KNIME also licenses KNIME Server, which enterprise functionality to productionize data science by offering functionality for collaboration, automation, deployment, and management. KNIME has offices in Zurich, Berlin, Konstanz, Austin, and Boston.

Achilles Therapeutics

Series B in 2019
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Seer

Series D in 2020
Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurological diseases, drive earlier treatment and improve patient outcomes.

TigerConnect, Inc.

Series D in 2020
TigerConnect is a provider of clinical communication solutions, TigerConnect helps physicians, nurses, and other staff communicate and collaborate more effectively, accelerating productivity, reducing costs, and improving patient outcomes. Trusted by more than 4,000 healthcare organizations, TigerConnect maintains 99.99% uptime and processes over 10 million messages each day. Its category-leading product innovations and advanced integrations with critical hospital systems deliver high value for hospitals and large health systems. Their commitment to client success is reflected in their broad support organization that works directly with clients at every stage to streamline communication workflows and achieve the highest possible ROI. The company was incorporated in 2010 and is headquartered in Santa Monica, California.

FlatFrog Laboratories AB

Venture Round in 2016
FlatFrog's mission is to bring to life the exciting new world of multi-touch computing and applications. Designed from inception for volume production, our patented technologies enable unmatched in-glass multi-touch performance for large and flat displays. FlatFrog was founded by Ola Wassvik and serial entrepreneur Christer FÃ¥hraeus. The company is privately held with headquarters in Lund, Sweden, near the bridge to Copenhagen, Denmark.

Zero Motorcycles Inc.

Venture Round in 2011
Zero Motorcycles, Inc. manufactures and supplies electric motorcycles. It offers street, dirt, and dual sport motorcycles; and accessories, apparel, fairings and bodywork, parts, tires and wheels, and upgrades. The company sells its products through dealers and online. The company has a strategic partnership with Polaris Inc. Zero Motorcycles, Inc. was formerly known as Electricross, Inc. The company was founded in 2006 and is based in Scotts Valley, California with an additional office in Noord-Scharwoude, the Netherlands.

FlatFrog Laboratories AB

Venture Round in 2014
FlatFrog's mission is to bring to life the exciting new world of multi-touch computing and applications. Designed from inception for volume production, our patented technologies enable unmatched in-glass multi-touch performance for large and flat displays. FlatFrog was founded by Ola Wassvik and serial entrepreneur Christer FÃ¥hraeus. The company is privately held with headquarters in Lund, Sweden, near the bridge to Copenhagen, Denmark.

Zero Motorcycles Inc.

Venture Round in 2012
Zero Motorcycles, Inc. manufactures and supplies electric motorcycles. It offers street, dirt, and dual sport motorcycles; and accessories, apparel, fairings and bodywork, parts, tires and wheels, and upgrades. The company sells its products through dealers and online. The company has a strategic partnership with Polaris Inc. Zero Motorcycles, Inc. was formerly known as Electricross, Inc. The company was founded in 2006 and is based in Scotts Valley, California with an additional office in Noord-Scharwoude, the Netherlands.

ElevateBio

Series B in 2020
ElevateBio is a operator of a portfolio of cell and gene therapy companies intended to develop, manufacture and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's most innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.

Zero Motorcycles Inc.

Venture Round in 2008
Zero Motorcycles, Inc. manufactures and supplies electric motorcycles. It offers street, dirt, and dual sport motorcycles; and accessories, apparel, fairings and bodywork, parts, tires and wheels, and upgrades. The company sells its products through dealers and online. The company has a strategic partnership with Polaris Inc. Zero Motorcycles, Inc. was formerly known as Electricross, Inc. The company was founded in 2006 and is based in Scotts Valley, California with an additional office in Noord-Scharwoude, the Netherlands.

Ashley Stewart, Inc.

Acquisition in 2016
Ashley Stewart is a global fashion brand that stands for uncompromising style, fashion, fit & empowerment for the woman who flaunts her curves.

IAM com

Venture Round in 2000
IAM.COM provides artists with a sophisticated multimedia portfolio.

Netcontinuum

Venture Round in 2005
NetContinuum, Inc. provides application controllers to deploy, secure, and manage enterprise Web applications. Its products include Web application firewalls that enable data center teams to secure existing enterprise applications; and Web application gateways, which provide application security, load balancing, content switching, connection pooling, caching, and GZIP compression to enable deployment of new enterprise applications. The company's controllers are used for managing business risk, DMZ consolidation, application deployment, instant PCI compliance, failed audit recovery, lowering DMZ TCO, and securing FTP. It also offers on-site installation, training, support, and other on-site custom engagements. NetContinuum serves the financial services, government, e-business, media and communications, ASP/software, healthcare, and education sectors. The company was founded in 1999 and is headquartered in Santa Clara, California. As of July 2007, NetContinuum, Inc. operates as a subsidiary of Barracuda Networks, Inc.

Cava Group, Inc.

Series C in 2017
Cava Group, Inc. owns and operates a chain of Greek and Mediterranean restaurants. It offers salads, dips, spreads, toppings, and dressings. The company has strategic partnerships with Garden School Foundation, Sow Much Good, Urban Roots, and Future Chefs. Cava Group, Inc. was founded in 2006 and is headquartered in Washington, District Of Columbia.

I-Mab HK

Post in 2020
I-Mab HK develops drugs to treat diabetes, cancer, and autoimmune diseases. The company develops preclinical compounds, including GX-P2; a long-acting PD-L1 drug for the treatment of inflammatory bowel diseases and GX-G8; a long-acting GLP-2 drug for the treatment of chemotherapy-induced diarrhea and short bowel syndrome. The company was formerly known as Tianzhenshi Biotechnology Company and changed its name to I-Mab HK in March 2017. The company is headquartered in Tianjin, China.

Rebound Therapeutics

Series B in 2017
Rebound has progressed rapidly over the past 18 months, having developed a unique array of devices to improve the procedural and clinical outcomes of many minimally invasive surgical procedures. In addition to rapid product development of its initial products, Rebound has assembled a world-class Scientific Advisory Board of leading MIS physicians, filed 14 patents to solidify its intellectual property platform and completed a series of pre-clinical studies supporting initial human-use, scheduled to begin soon.

Unity Biotechnology, Inc.

Series C in 2018
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.

Faze Medicines

Series A in 2020
Faze Medicines, a pharmaceutical company, develops interventions against driver of disease pathology. It develops small molecule drugs for initial therapeutic focus areas, such as amyotrophic lateral sclerosis and myotonic dystrophy type 1. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Cava Group, Inc.

Series B in 2015
Cava Group, Inc. owns and operates a chain of Greek and Mediterranean restaurants. It offers salads, dips, spreads, toppings, and dressings. The company has strategic partnerships with Garden School Foundation, Sow Much Good, Urban Roots, and Future Chefs. Cava Group, Inc. was founded in 2006 and is headquartered in Washington, District Of Columbia.

GenSight Biologics

Post in 2020
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.

Thrive Market

Convertible Note in 2019
Thrive Market, Inc. operates a membership-based online shopping club that gives access to wholesome food and products in everyday sizes at wholesale prices. The company offers products in food, health, babies and kids, home, and pet, as well as beauty, bath, and body categories. It serves residential and commercial customers in the United States. The company was incorporated in 2015 and is based in Culver City, California.
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company’s lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.

Valo Health

Series B in 2021
Valo Health is a new type of technology company, uniting human and machine intelligence aiming to accelerate the creation of life-changing treatments.

FlatFrog Laboratories AB

Venture Round in 2012
FlatFrog's mission is to bring to life the exciting new world of multi-touch computing and applications. Designed from inception for volume production, our patented technologies enable unmatched in-glass multi-touch performance for large and flat displays. FlatFrog was founded by Ola Wassvik and serial entrepreneur Christer FÃ¥hraeus. The company is privately held with headquarters in Lund, Sweden, near the bridge to Copenhagen, Denmark.

Inotrem S.A

Series B in 2019
Inotrem S.A discovers and develops novel treatments in the field of inflammatory pathologies with a focus on critical care. Its technology includes a TREM-1 inhibitor, nangibotide (LR12), that aims to control excessive inflammation in severe sepsis patients. The company was founded in 2013 and is based in Paris, France.

Kronos Bio, Inc.

Series A in 2019
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

ViraCyte

Series B in 2019
AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials. The company was founded in 2013 and headquartered in Houston, Texas.

Abound Solar

Private Equity Round in 2010
Abound Solar produces next-generation, thin film photovoltaic modules intended to deliver the lowest levelized cost of electricity.

Lyndra Inc

Series B in 2019
Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximize global health impact and lower overall healthcare costs.

Kaleido BioSciences

Series C in 2018
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.

Booster Fuels, Inc.

Series C in 2019
Booster Fuels, Inc. provides on-demand fuel delivery services. It offers a mobile application that enables users to order fuel. The company also provides corporate programs for employees. It delivers fuel in Austin, Fort Worth, the Los Angeles Area, Nashville, Orange County, the San Francisco Bay Area, and Seattle. Booster Fuels, Inc. was incorporated in 2014 and is based in San Mateo, California.

ZenRobotics Ltd.

Series A in 2012
ZenRobotics, founded in 2007, is a Finnish high-tech company specializing in robotic recycling technology. The company’s main product is ZenRobotics Recycler, a waste sorting system which separates raw materials from waste. ZenRobotics Recycler is the world’s first robotic waste sorting system. The robots accurately separate chosen waste fractions from solid waste streams. Designed to increase the efficiency and lower the cost of waste separation, ZRR is the next generation of recycling.

Unity Biotechnology, Inc.

Series B in 2017
Unity Biotechnology designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected.

Autobahn Therapeutics

Series B in 2020
Autobahn Therapeutics, Inc. develops small molecule therapies for the treatment of central nervous system (CNS) disorders. The company develops ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS), and adrenomyeloneuropathy (AMN). Autobahn Therapeutics, Inc. was formerly known as Llama Therapeutics, Inc. and changed its name to Autobahn Therapeutics, Inc. in December 2019. The company was incorporated in 2017 and is based in San Diego, California.

Apos Medical Assets Ltd.

Series B in 2014
Apos Medical Assets Ltd. provides non-surgical services for orthopedics. It offers shoes for chronic pain from conditions like osteoarthritis of the knee. The company was founded in 2004 and is based in New York, New York. It has operations in Israel, Singapore, and the United Kingdom.

KSQ Therapeutics, Inc.

Series C in 2018
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

Amount

Series C in 2020
Amount, Inc. designs and develops mobile banking solutions for financial institutions. The company offers Amount 360, a cloud-based solution that provides full-stack solutions, omnichannel integration, mitigation strategies, integration hubs, and a proprietary fraud model. The company also offers solutions for personal loans, credit cards, deposit accounts, and point-of-sale. Amount, Inc. was incorporated in 2018 and is based in Chicago, Illinois.

Erasca

Series B in 2020
Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations, providing patients with new potential solutions to not just treat but cure cancer. It was founded in 2018 and headquartered in San Diego, California.
Triplet Therapeutics, Inc. develops therapeutics and treatments for triplet disorders. It develops treatment for repeat expansion disorders, including Huntington’s disease, myotonic dystrophy, and spinocerebellar ataxias. Triplet Therapeutics, Inc. was formerly known as rzna, Inc. The company was founded in 2018 and is based in Cambridge, Massachusetts.

Taysha Gene Therapies

Series B in 2020
Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications.

LEXEO Therapeutics

Series A in 2021
LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (single genemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline.

Bizagi

Private Equity Round in 2017
Bizagi Limited provides digital business platform-as-a-service for process modeling and automation, modernization, and transformation. It offers Bizagi Modeler that enables business experts to design, document, and evolve their process model; Bizagi Studio that transforms process models into applications and workflows; and Bizagi Engine that executes and controls the business processes automated by Bizagi Studio. The company was incorporated in 2005 and is based in Chalfont St Peter, United Kingdom with additional offices in Spain, Germany, North America, New York, Chicago, Dallas, Latam, Brazil, Chile, Mexico, and Washington, D.C. Bizagi Limited operates as a subsidiary of Vision Software S.A.

Seer

Series B in 2018
Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurological diseases, drive earlier treatment and improve patient outcomes.

Mission Lane

Series A in 2019
Mission Lane LLC provides credit card services to subprime consumers. The company leverages advanced technology, data analytics, and machine learning to provide its services to the consumers. The company's digital self-service tools make it easier for customers to stay on top of their accounts, further helping them succeed in improving their credit scores. Mission Lane LLC was founded in 2018 and is headquartered in Atlanta, Georgia with additional offices in Richmond, Virginia; Pennsylvania; New York; New Jersey; and Toronto, Canada.

PatientsLikeMe, Inc.

Venture Round in 2017
PatientsLikeMe is a personalized health network of an integrated community, health management, and real-world data platform. It helps people find new options for treatments, connect with others, and take action to improve their outcomes. The company has worked with every major pharmaceutical company and a range of government organizations to bring the patient voice to research, development, and public policy. With more than 600,000 members, PatientsLikeMe is a trusted source for real-world disease information and a clinically robust resource that has published more than 100 research studies. The Boston, Massachusetts-located company was founded by Ben Heywood, James Heywood, and Jeff Cole in 2004

AirTies Wireless Networks

Series B in 2012
Founded in 2004, AirTies is the most widely deployed provider of Wi-Fi Mesh solutions to operators around the globe. AirTies designs and develops software and hardware that wirelessly streams Internet connections and high definition video to multiple rooms and screens. The comprehensive product portfolio includes broadband Internet devices and Internet-based television set-top boxes. Its award winning technology enables seamless wireless integration at the touch of a button, increased wireless speeds, and coverage throughout subscribers’ entire homes. AirTies has an installed base of over 15 million devices worldwide. AirTies’ customers include: Sky (including Sky Q in the UK, Germany, Austria, and Italy), Vodafone, Singtel, Swisscom, Frontier, Waoo, and many others operators. More information is available at www.AirTies.com.

Morphic Holding, Inc.

Series B in 2018
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group.

Viseon Spine

Series A in 2017
Viseon, Inc. operates as a medical device company. It has developed the Voyant technology for use in both posterior and lateral access MIS spine procedures. The company’s technology offers a single-use disposable alternative to surgical microscopes, endoscopes and loupes, projecting the operative field onto a high definition flat panel display within the OR and to remote locations. Viseon, Inc. was incorporated in 2017 and is based in Irvine, California.

Thrive Earlier Detection

Series A in 2019
Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3.

Gossamer Bio, Inc.

Series B in 2018
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.

SNAZ.com

Series A in 2000
A global personal shopping assistant for portals and consumers.

Kronos Bio, Inc.

Private Equity Round in 2020
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

Generation Bio Co.

Series C in 2020
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.

Schrodinger

Series E in 2019
Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990, has over 400 employees and is engaged with customers and collaborators in more than 70 countries. To learn more visit www.schrodinger.com.
Scholar Rock, Inc., a biotechnology company, discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

Fluidigm

Series D in 2004
Fluidigm Corporation develops and distributes systems based on the properties of integrated fluidic circuits to control precisely fluids on a nano volume scale. The company's product line includes the TOPAZ system, which is used for protein crystallization; and the BioMark system, which is used for genetic analysis. Fluidigm Corporation was founded as Mycometrix Corporation in 1999 and was renamed as Fluidigm Corporation in 2001. The company is based in San Francisco, California.

Arcus Biosciences, Inc.

Series C in 2017
Arcus Biosciences is biotech company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub.

Netcontinuum

Series B in 2001
NetContinuum, Inc. provides application controllers to deploy, secure, and manage enterprise Web applications. Its products include Web application firewalls that enable data center teams to secure existing enterprise applications; and Web application gateways, which provide application security, load balancing, content switching, connection pooling, caching, and GZIP compression to enable deployment of new enterprise applications. The company's controllers are used for managing business risk, DMZ consolidation, application deployment, instant PCI compliance, failed audit recovery, lowering DMZ TCO, and securing FTP. It also offers on-site installation, training, support, and other on-site custom engagements. NetContinuum serves the financial services, government, e-business, media and communications, ASP/software, healthcare, and education sectors. The company was founded in 1999 and is headquartered in Santa Clara, California. As of July 2007, NetContinuum, Inc. operates as a subsidiary of Barracuda Networks, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company’s second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.

Seer

Series D in 2019
Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurological diseases, drive earlier treatment and improve patient outcomes.